Ticker
ABEO

Price
2.40
Stock movement down
-0.05 (-2.04%)
Company name
Abeona Therapeutics Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Capitalización del mercado
41.22M
Valor de Ent
58.84M
Precio/Ventas
9.48
Precio/Reservar
2.67
Rendimiento del div.
-
Crecimiento del div.
-
Años de crecimiento
-
Pago FCF
-
Seguimiento de P/E
-
P/E A plazo
-
PEG
-
EPS crecimiento
-
Rendimiento a 1 año
727.59%
Rendimiento a 3 años
4.06%
Rendimiento a 5 años
-30.24%
Rendimiento a 10 años
-20.25%
Última actualización: 2023-03-22
Get the latest news and real-time alerts from Abeona Therapeutics Inc. (ABEO) stock at Seeking Alpha.
29 de marzo de 2023

iO Charts is a Seeking Alpha partner

Get the latest news and real-time alerts from Abeona Therapeutics Inc. (ABEO) stock at Seeking Alpha.
1 de diciembre de 2022

iO Charts is a Seeking Alpha partner

DIVIDENDOS

ABEO no paga dividendos
Get the latest news and real-time alerts from Abeona Therapeutics Inc. (ABEO) stock at Seeking Alpha.
14 de noviembre de 2022

iO Charts is a Seeking Alpha partner

Get the latest news and real-time alerts from Abeona Therapeutics Inc. (ABEO) stock at Seeking Alpha.
3 de noviembre de 2022

iO Charts is a Seeking Alpha partner

VALORACIÓN

Relaciones de valoración

Loading...
Datos de relaciones de valoración
Seguimiento de P/E-
Precio de OCF-
Precio de FCF-
Precio de EBITDA-
EV a EBITDA-

Valoración (ventas/valor contable)

Loading...
Datos de valoración (ventas/valor contable)
Precio de venta9.48
Precio para reservar2.67
EV a ventas13.54
Get the latest news and real-time alerts from Abeona Therapeutics Inc. (ABEO) stock at Seeking Alpha.
3 de noviembre de 2022

iO Charts is a Seeking Alpha partner

Results from the pivotal VITAL study, using EB-101 for the treatment of patients with RDEB are expected to be released before the end of 2022. Read more here.
19 de octubre de 2022

iO Charts is a Seeking Alpha partner

FINANZAS

Por acción

Loading...
Datos por acción
Recuento actual de acciones17.18M
EPS (TTM)-13.28
FCF por acción (TTM)-7.64

Declaración de ingresos

Loading...
Datos de la declaración de ingresos
Ingresos (TTM)4.35M
Beneficio bruto (TTM)4.00M
Ingresos operativos(TTM)-84.63M
Ingresos netos (TTM)-85.25M
EPS (TTM)-13.28
EPS (a 1 año)-1.79

Márgenes

Loading...
Datos de márgenes
Margen bruto (TTM)91.95%
Margen operativo (TTM)-1947.33%
Margen de beneficios (TTM)-1961.64%

Balance

Loading...
Por favor, cree una cuenta gratuita o inicie sesión para acceder a este gráfico
Datos de balance
Efectivo5.73M
Créditos netos1.05M
Total de activos corrientes25.50M
Fondo de comercio0.00
Activos intangibles0.00
Propiedad, planta y equipo0.00
Activos totales38.76M
Cuentas por pagar1.75M
Deuda actual a corto/largo plazo8.29M
Total de pasivos corrientes12.60M
Total de pasivos23.35M
Fondos propios de los accionistas15.41M
Activos tangibles netos15.41M

Flujo de efectivo

Loading...
Por favor, cree una cuenta gratuita o inicie sesión para acceder a este gráfico
Datos de flujo de efectivo
Flujo de caja operativo (TTM)-46.16M
Gastos de capital (TTM)2.91M
Flujo libre de efectivo (TTM)-49.07M
Dividendos pagados (TTM)0.00

Rendimiento financiero

Loading...
Por favor, cree una cuenta gratuita o inicie sesión para acceder a este gráfico
Datos de rendimiento financiero
Rendimiento de los fondos propios-553.12%
Rendimiento de los activos-219.95%
Rendimiento del capital invertido-495.00%
Rendimiento de efectivo del capital invertido-284.93%
Get the latest news and real-time alerts from Abeona Therapeutics Inc. (ABEO) stock at Seeking Alpha.
4 de octubre de 2022

iO Charts is a Seeking Alpha partner

Get the latest news and real-time alerts from Abeona Therapeutics Inc. (ABEO) stock at Seeking Alpha.
3 de octubre de 2022

iO Charts is a Seeking Alpha partner

INFORMACIÓN SOBRE LAS ACCIONES

Gráfico de acciones

Loading...
Datos sobre el precio de las acciones
Abierto2.46
Máximo diario2.49
Mínimo diario2.38
Volumen diario49K
Máximo histórico47188.00
Estimación de analistas a 1 año21.33
Beta1.25
EPS (TTM)-13.28
Dividendo por acción-
Fecha ex-div22 Jul 2022
Próxima fecha de beneficios29 Mar 2023

Potencial de desventaja

Loading...
Datos del potencial de desventaja
ABEOS&P500
Caída del precio actual desde el máximo histórico-99.99%-17.92%
La mayor caída de precio-100.00%-56.47%
Fecha de la mayor caída17 Jun 20229 Mar 2009
Caída promedio del máximo-92.06%-11.51%
Tiempo promedio para un nuevo máximo406 days13 days
Tiempo máximo hasta el nuevo máximo7600 days1805 days
The following slide deck was published by Abeona Therapeutics Inc.
17 de agosto de 2022

iO Charts is a Seeking Alpha partner

Get the latest news and real-time alerts from Abeona Therapeutics Inc. (ABEO) stock at Seeking Alpha.
11 de agosto de 2022

iO Charts is a Seeking Alpha partner

DETALLES DE LA EMPRESA
ABEO (Abeona Therapeutics Inc) company logo
Mercado
41.22M
Categoría de Mercado
Small-cap
Descripción
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
Empleados
90
Relaciones con inversionistas
-
Archivos de la SEC
CEO
Joao Siffert
País
USA
Ciudad
New York
Tipo de acciones
Common stock
CCC estatus
-
Frecuencia de Dividendos
-
EVENTOS Y PRESENTACIONES
EventosPresentaciones
Loading...
Get the latest news and real-time alerts from Abeona Therapeutics Inc. (ABEO) stock at Seeking Alpha.
20 de julio de 2022

iO Charts is a Seeking Alpha partner

Get the latest news and real-time alerts from Abeona Therapeutics Inc. (ABEO) stock at Seeking Alpha.
5 de julio de 2022

iO Charts is a Seeking Alpha partner

ENTENDER EL NEGOCIO
Loading...
Get the latest news and real-time alerts from Abeona Therapeutics Inc. (ABEO) stock at Seeking Alpha.
19 de mayo de 2022

iO Charts is a Seeking Alpha partner

Abeona Therapeutics Inc. (NASDAQ:NASDAQ:ABEO) Q1 2022 Earnings Conference Call May 17, 2022 8:30 AM ETCompany ParticipantsVishwas Seshadri - Chief Executive OfficerJoseph Vazzano - Chief...
17 de mayo de 2022

iO Charts is a Seeking Alpha partner

NOVEDADES DE LA EMPRESA
Todas las novedadesComunicados de prensa
We can readily understand why investors are attracted to unprofitable companies. For example, although...
31 de marzo de 2023
Expects to submit BLA for EB-101 to FDA in late-2Q/early-3Q 2023 based on positive Phase 3 VIITAL™ study results announced in 4Q 2022 Advancing AAV-based gene therapy candidates toward IND studies in ...
29 de marzo de 2023
NEW YORK and CLEVELAND, March 24, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new employees who joined Abeona. On March 23, 2023, A...
24 de marzo de 2023
NEW YORK and CLEVELAND, March 16, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that additional data from its pivotal Phase 3 VIITAL™ study of EB-101 for recessive d...
16 de marzo de 2023
Advancing AAV-based gene therapy candidates toward IND studies on encouraging animal proof of concept data in Stargardt Disease, X-linked Retinoschisis (XLRS), and Autosomal Dominant Optic Atrophy (AD...
14 de marzo de 2023
Following positive topline data from Phase 3 VIITAL™ study of EB-101 with both co-primary endpoints met, Abeona plans to submit BLA to U.S. FDA in 2Q 2023 Company well-funded with expected cash runway...
14 de noviembre de 2022
Cantor Fitzgerald raised the price target on Abeona Therapeutics Inc (NASDAQ: ABEO) from $22 to $40 after adjusting the market model/ increasing the probability of success for EB-101. Last week, the c...
8 de noviembre de 2022
Abeona Therapeutics Inc (NASDAQ: ABEO) announced topline data from its pivotal Phase 3 VIITAL study of EB-101 for recessive dystrophic epidermolysis bullosa (RDEB). The VIITAL study met its two co-pri...
3 de noviembre de 2022
NEW YORK and CLEVELAND, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) announced today that it has entered into a securities purchase agreement to sell 7,065,946 shares of i...
3 de noviembre de 2022
Co-primary endpoint measuring >50% wound healing, other endpoints measuring >75% and complete wound healing at six months all met Co-primary endpoint measuring pain reduction at six months met; greate...
3 de noviembre de 2022
Página siguiente
Get the latest news and real-time alerts from Abeona Therapeutics Inc. (ABEO) stock at Seeking Alpha.
17 de mayo de 2022

iO Charts is a Seeking Alpha partner

Get the latest news and real-time alerts from Abeona Therapeutics Inc. (ABEO) stock at Seeking Alpha.
13 de mayo de 2022

iO Charts is a Seeking Alpha partner